L&T-TECHNOLOGY-SERVICES
24.5.2023 10:31:34 CEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced its partnership with Critical Manufacturing, the provider of innovative, future-ready Manufacturing Execution Systems (MES). The strategic alliance initially sees the companies working with the multi-national engineering group, Danfoss, to implement a comprehensive digital framework that harnesses cutting-edge technologies and next-gen capabilities.
LTTS works with plant operators worldwide to optimize efficiency, improve productivity, and simplify operations while ensuring compliance with global sustainability standards. The Critical Manufacturing MES is designed from the ground-up to embrace Industry 4.0 technologies and provide a comprehensive pathway to smart manufacturing of sophisticated and complex products.
Abhishek Sinha, Chief Operating Officer and Board Member at L&T Technology Services, said, “The advanced Critical Manufacturing MES complements our industry-leading technology services. Our combined expertise and understanding of the markets we serve, supported by the most modern MES platform for Industry 4.0 success, will enable us to drive better business outcomes for our manufacturing and industrial clients.”
The selection of the Critical Manufacturing MES is part of a Smart Manufacturing Journey for Danfoss, with aims to achieve greater visibility, create transparency, enhance quality, secure IT/OT operations, and faster time to market. The platform will help standardize operations and processes to improve business process outcomes, compliance, and risk management.
“We selected the Critical Manufacturing MES because of its best of suite capabilities that allows users to take advantage of different functionalities within the same unified architecture which is expected from a modern MOM platform,” comments Tarun Chopra, Sr. Director, Head of Manufacturing Service, Danfoss Group IT. “The product has been designed for the future and will enable us to drive innovation within our business. The improvement in operational efficiency and cost management control gives us a clear return on investment and will enable us to respond more quickly to changing market demands.”
Danfoss has a large global presence with 97 factories in more than 20 countries worldwide. The initial MES deployment will be within the Danfoss Climate Solutions segment. This segment is focused on leading the way to a greener future with integrated, energy-efficient heating and cooling solutions that enhance sustainability across areas including buildings, cold chains, industry, and infrastructure.
LTTS offers consulting, engineering, and implementation services to drive global digital transformation initiatives across sectors including semiconductors, electronics, medical devices, and discrete manufacturing. These are sectors where the Critical Manufacturing MES offers rich functionality and is recognized as being one of the most innovative, flexible, and comprehensive platforms to support businesses on their journey to Industry 4.0.
Chopra continues, “While the Critical Manufacturing MES is being implemented in our Climate Solutions segment, we are also in the process of defining a global MES roadmap. The ease of deployment of the platform and its performance is an important element as we continue our pathway to digitalization and standardization throughout the global Danfoss group.”
“The use of DevOps within our platform means that new functionality and upgrades can be quickly and easily deployed and new sites added, ensuring the system is always future-ready,” comments Augusto Vilarinho, Head of Global Sales at Critical Manufacturing. “This supports Danfoss, LTTS and Critical Manufacturing’s aligned visions to take manufacturing to a future state that will deliver new benchmarks in the levels of efficiency, quality, agility, and sustainability.”
“The Danfoss digitalization project is an important starting point for our partnership. Going forward, we will work together to uncover opportunities and drive better business outcomes for our joint global customers. Together, we will engineer a sustainable tomorrow and build a better future for the world,” adds LTTS’ COO Abhishek Sinha.
Critical Manufacturing works closely with a strong network of certified global partners to ensure customers have access to domain and application experts and are supported throughout their projects.
Vilarinho concludes, “This is an exciting time for our companies, and we are looking forward to a long relationship with Danfoss and LTTS as a strategic partner. I strongly believe that together we will reach new goals and raise the bar for manufacturing worldwide.”
About Danfoss A/S:
Danfoss engineers solutions that increase machine productivity, reduce emissions, lower energy consumption, and enable electrification. Our solutions are used in such areas as refrigeration, air conditioning, heating, power conversion, motor control, industrial machinery, automotive, marine, and off- and on-highway equipment. We also provide solutions for renewable energy, such as solar and wind power, as well as district-energy infrastructure for cities. Our innovative engineering dates back to 1933. Danfoss is family-owned, employing more than 42,000 people, serving customers in more than 100 countries through a global footprint of 97 factories. www.danfoss.com
About Critical Manufacturing
Critical Manufacturing, leader in the Gartner Magic Quadrant and a subsidiary of ASMPT, provides the most modern, flexible and configurable manufacturing execution system (MES) available. Critical Manufacturing MES helps manufacturers stay ahead of stringent product traceability and compliance requirements; reduce risk with inherent closed-loop quality; integrate seamlessly with enterprise systems and factory automation, and provide deep intelligence and visibility of global production operations.
As a result, our customers are Industry 4.0 ready. They can compete effectively and profitably by easily adapting their operations to changes in demand, opportunity, or requirements, anywhere, at any time. For more information, visit www.criticalmanufacturing.com
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 22,200 employees spread across 22 global design centers, 28 global sales offices and 99 innovation labs as of March 31, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005684/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom